-$1.41 EPS Expected for Prothena Corporation PLC (PRTA) This Quarter
Wall Street analysts expect that Prothena Corporation PLC (NASDAQ:PRTA) will announce earnings per share (EPS) of ($1.41) for the current quarter, according to Zacks. Four analysts have issued estimates for Prothena Corporation PLC’s earnings. The highest EPS estimate is ($1.21) and the lowest is ($1.54). Prothena Corporation PLC posted earnings of ($1.26) per share during the same quarter last year, which would suggest a negative year over year growth rate of 11.9%. The company is expected to announce its next quarterly earnings results after the market closes on Tuesday, November 7th.
On average, analysts expect that Prothena Corporation PLC will report full-year earnings of ($4.51) per share for the current year, with EPS estimates ranging from ($4.80) to ($3.94). For the next financial year, analysts expect that the company will post earnings of ($5.17) per share, with EPS estimates ranging from ($6.82) to ($4.25). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Prothena Corporation PLC.
Prothena Corporation PLC (NASDAQ:PRTA) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.43. The firm had revenue of $26.81 million for the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The business’s revenue was up 7951.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.18) earnings per share.
Several equities analysts have recently commented on PRTA shares. BidaskClub raised shares of Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Jefferies Group LLC assumed coverage on shares of Prothena Corporation PLC in a research note on Monday, July 10th. They set a “buy” rating and a $100.00 price objective for the company. Deutsche Bank AG set a $73.00 price target on shares of Prothena Corporation PLC and gave the stock a “buy” rating in a research note on Monday, October 23rd. Cantor Fitzgerald reissued a “buy” rating and issued a $79.00 price target on shares of Prothena Corporation PLC in a research note on Thursday, September 28th. Finally, ValuEngine downgraded shares of Prothena Corporation PLC from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $78.58.
Prothena Corporation PLC (NASDAQ:PRTA) opened at $61.56 on Tuesday. Prothena Corporation PLC has a 52 week low of $40.59 and a 52 week high of $70.00.
In other news, Director Dennis J. Selkoe sold 3,500 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $64.17, for a total transaction of $224,595.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Tara Nickerson sold 17,500 shares of the stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the sale, the insider now owns 19,500 shares in the company, valued at approximately $1,240,200. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,424 shares of company stock worth $1,922,787. Corporate insiders own 3.10% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Teacher Retirement System of Texas purchased a new stake in shares of Prothena Corporation PLC during the third quarter valued at approximately $206,000. Rhumbline Advisers boosted its holdings in Prothena Corporation PLC by 3.6% in the third quarter. Rhumbline Advisers now owns 46,872 shares of the biotechnology company’s stock worth $3,036,000 after purchasing an additional 1,610 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in Prothena Corporation PLC by 128.1% in the third quarter. New York State Common Retirement Fund now owns 94,900 shares of the biotechnology company’s stock worth $6,147,000 after purchasing an additional 53,300 shares during the last quarter. HL Financial Services LLC purchased a new stake in Prothena Corporation PLC in the third quarter worth approximately $208,000. Finally, Swiss National Bank boosted its holdings in Prothena Corporation PLC by 2.1% in the third quarter. Swiss National Bank now owns 63,600 shares of the biotechnology company’s stock worth $4,119,000 after purchasing an additional 1,300 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/1-41-eps-expected-for-prothena-corporation-plc-prta-this-quarter/1685015.html.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.